Researchers present advance in re-treatment with CAR T therapy


Researchers from the University of Pennsylvania’s Abramson Cancer Center presented preliminary results of an ongoing Phase I clinical trial demonstrating successful re-treatment with CAR T cell therapy for patients whose cancers relapsed after previous CAR T therapy at the 2022 American Society of Hematology (ASH) Annual Meeting.

The best part of ‘White Lotus’ is the online community it’s created

Previous article

Troubleshooting the mystery of post-COVID insomnia with a sleep tracker

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations